Milestone Scientific Inc.

Hi, everyone. Welcome to the Milestone Scientific, Inc. First Quarter 2026 Financial Results and Business Update Conference Call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, James Carbonara from Hayden IR. The floor is yours.

Thank you, Operator. Before we begin, please note that today's call will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Please refer to our earnings specialties as well as our filings with the SEC, including our 2025 Form 10-K for discussion of these risks. A replay of this call will be available shortly after its conclusion. With that, I'll turn the call over to our CEO, Eric Hines.

Thank you, James, and good morning, everybody, and thank you for doing our call today. I especially want to thank everybody who participated in our pipe in April and your continued support for Milestone. It is greatly appreciated. Our first quarter results reflect continued progress as we execute on the foundation we established in 2025. We remain focused on building a disciplined operating model. We're spending as aligned with revenue generation. and Clear Return on Investment. That focus is reflected in our results. We maintained a relatively stable revenue base in the quarter, despite the inability to ship certain booked orders to the Middle East due to the ongoing global conflict in the region. Even with that headwind, we reduced operating expenses by approximately $1.3 million, or more than 30% year over year, significantly narrowing our losses while we aligned the company for growth. At the same time, we are beginning to see early signs of traction in the areas that we see as key growth drivers. Starting with our dental business, which remains the backbone of the company, we continue to execute on the national rule of our ambassador program, following its expansion in January, resulting in 173 applications, 73 active ambassadors, and 25 new demos and multiple new sales. Engagement levels have been encouraging, And while we expect the financial impact to build over time, we believe this initiative is strengthening our commercial presence and positioning us for improved performance in the back half of the year. Internationally, we continue to pursue additional registrations which we believe can open meaningful new markets over time. Turning to the medical side, coffee flow continues to gain traction and is becoming an increasingly important part of our growth strategy. In the first quarter, medical revenue more than doubled year over year, reflecting early stage adoption and growing interest from clinicians. While we are still in the early innings, the progress reinforces our view that the CompuFlow represents a significant long-term opportunity for the company. We also continue to build our infrastructure required to support that growth. Following the launch of our CompuFlow Advisor Program in February, We now have more than eight physician partners actively engaged in six pending, supported by a dedicated reimbursement infrastructure, with over 50 claims submitted across three MACs, specifically Novotox, Palmetto, and First Coast. This is a critical component of our strategy, as adoption in the medical market is closely tied to both clinical validation and reimbursement support. In addition, we remain focused on expanding Medicare coverage. onboarding seven new distribution partners and advancing opportunities with both national and local VA channels. Furthermore, we have started a digital marketing campaign across multiple channels for CoffeeFlow, resulting in 152 leads. These initiatives are designed to convert early clinical interest into sustained utilization over time. Subsequent to the end of the quarter, we strengthened our balance sheet through a 2.15 million financing. This provides us with additional flexibility to invest in key growth initiatives, including sales expansion, inventory, and digital marketing, while maintaining the disciplined approach to capital allocation that we've emphasized since last year. Turning to our outlook, we are reaffirming our guidance, our 2026 guidance. We continue to expect total revenue in the range of $9.8 million to $10.2 million, representing a double-digit year-over-year growth. Within that, we expect copy flow revenue to grow at an even greater pace over the remainder of 2025. Combined with the structural cost reductions implemented last year, this level of growth is expected to drive improved operating leverage and a meaningful reduction in cash burn. Our goal is to reach cash flow breakeven in early 2027 through disciplined execution, investing only where we see clear returns, and building a business that can deliver sustainable Long-Term Shareholder Value. I'll now turn the call over to Keisha to review our financials. Keisha?